Literature DB >> 25200411

Breast cancer: Zoledronic acid--more than just a bone drug.

Aju Mathew1, Adam Brufsky1.   

Abstract

Several clinical trials have investigated the antitumour effect of bisphosphonates when used as adjuvant treatment for early stage breast cancer. Among these, the results of the AZURE trial, although negative,highlight the potential benefit of treatment with zoledronic acid in postmenopausal women with high-risk early stage breast cancer.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25200411     DOI： 10.1038/nrclinonc.2014.152

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  8 in total

1.  Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.

Authors:  Adam M Brufsky; W Graydon Harker; J Thaddeus Beck; Linda Bosserman; Charles Vogel; Christopher Seidler; Lixian Jin; Ghulam Warsi; Eliza Argonza-Aviles; John Hohneker; Solveig G Ericson; Edith A Perez
Journal:  Cancer       Date:  2011-10-10       Impact factor: 6.860

Review 2.  Potential anticancer properties of bisphosphonates: insights from preclinical studies.

Authors:  Philippe Clezardin
Journal:  Anticancer Agents Med Chem       Date:  2012-02       Impact factor: 2.505

3.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Authors:  Michael Gnant; Brigitte Mlineritsch; Herbert Stoeger; Gero Luschin-Ebengreuth; Dietmar Heck; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Gunda Pristauz; Thomas Bauernhofer; Holger Eidtmann; Wolfgang Eiermann; Guenther Steger; Werner Kwasny; Peter Dubsky; Gerhard Hochreiner; Ernst-Pius Forsthuber; Christian Fesl; Richard Greil
Journal:  Lancet Oncol       Date:  2011-06-05       Impact factor: 41.316

4.  Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

Authors:  Alexander H G Paterson; Stewart J Anderson; Barry C Lembersky; Louis Fehrenbacher; Carla I Falkson; Karen M King; Lorna M Weir; Adam M Brufsky; Shaker Dakhil; Thomas Lad; Luis Baez-Diaz; Julie R Gralow; André Robidoux; Edith A Perez; Ping Zheng; Charles E Geyer; Sandra M Swain; Joseph P Costantino; Eleftherios P Mamounas; Norman Wolmark
Journal:  Lancet Oncol       Date:  2012-06-14       Impact factor: 41.316

5.  Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

Authors:  R Coleman; R de Boer; H Eidtmann; A Llombart; N Davidson; P Neven; G von Minckwitz; H P Sleeboom; J Forbes; C Barrios; A Frassoldati; I Campbell; O Paija; N Martin; A Modi; N Bundred
Journal:  Ann Oncol       Date:  2012-10-09       Impact factor: 32.976

6.  Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

Authors:  Robert Coleman; David Cameron; David Dodwell; Richard Bell; Caroline Wilson; Emma Rathbone; Maccon Keane; Miguel Gil; Roger Burkinshaw; Robert Grieve; Peter Barrett-Lee; Diana Ritchie; Victoria Liversedge; Samantha Hinsley; Helen Marshall
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

Review 7.  Bisphosphonates in breast cancer.

Authors:  Aju Mathew; Adam Brufsky
Journal:  Int J Cancer       Date:  2014-05-20       Impact factor: 7.396

8.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976
  8 in total
  3 in total

1.  Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.

Authors:  Alison K Esser; Anne H Schmieder; Michael H Ross; Jingyu Xiang; Xinming Su; Grace Cui; Huiying Zhang; Xiaoxia Yang; John S Allen; Todd Williams; Samuel A Wickline; Dipanjan Pan; Gregory M Lanza; Katherine N Weilbaecher
Journal:  Nanomedicine       Date:  2015-10-27       Impact factor: 5.307

2.  Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.

Authors:  H Qiao; T-y Wang; Z-f Yu; X-g Han; X-q Liu; Y-g Wang; Q-m Fan; A Qin; T-t Tang
Journal:  Cell Death Dis       Date:  2016-02-11       Impact factor: 8.469

3.  Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.

Authors:  Cinzia Borghese; Naike Casagrande; Eliana Pivetta; Alfonso Colombatti; Mariarosaria Boccellino; Evzen Amler; Nicola Normanno; Michele Caraglia; Giuseppe De Rosa; Donatella Aldinucci
Journal:  Oncotarget       Date:  2017-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.